Press release February 4, 2022 Message from the CEO IBT's ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is accomplished
Investegate announcements from Infant Bacterial Therapeutics, Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
Investegate announcements from Infant Bacterial Therapeutics, The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after.
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The Connection